BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31470997)

  • 1. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
    Chai KY; Boyke Berahmana AA; Morison IM
    Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
    Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
    Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
    Ren Z; Spaargaren M; Pals ST
    Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.
    Stifter S; Babarović E; Valković T; Seili-Bekafigo I; Stemberger C; Nacinović A; Lucin K; Jonjić N
    Diagn Pathol; 2010 May; 5():30. PubMed ID: 20482792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust isolation of malignant plasma cells in multiple myeloma.
    Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
    Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD138 shedding in plasma cell myeloma.
    Grigoriadis G; Whitehead S
    Br J Haematol; 2010 Aug; 150(3):249. PubMed ID: 20433680
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma cell myeloma with histiocyte-like morphology.
    Zhu J; Pan B; Yao J; Guo W
    Int J Hematol; 2017 Sep; 106(3):307-309. PubMed ID: 28555415
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features.
    Grogan TM
    Semin Diagn Pathol; 2003 Aug; 20(3):211-25. PubMed ID: 14552432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
    Qasaimeh MA; Wu YC; Bose S; Menachery A; Talluri S; Gonzalez G; Fulciniti M; Karp JM; Prabhala RH; Karnik R
    Sci Rep; 2017 Apr; 7():45681. PubMed ID: 28374831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin lesions in a patient with multiple myeloma.
    Mebius M; Westerman M; Smorenburg CH
    Neth J Med; 2014 Jul; 72(6):330, 334. PubMed ID: 25319859
    [No Abstract]   [Full Text] [Related]  

  • 15. CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry.
    Barksdale B; Leith CP
    Blood; 2020 Oct; 136(14):1698. PubMed ID: 33002126
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clear cell myeloma: report of a case].
    Xu H; Li J; Yang S
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):196-7. PubMed ID: 24842022
    [No Abstract]   [Full Text] [Related]  

  • 17. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.
    Joshi R; Horncastle D; Elderfield K; Lampert I; Rahemtulla A; Naresh KN
    J Clin Pathol; 2008 Feb; 61(2):213-6. PubMed ID: 17526802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
    Malherbe JAJ; Fuller KA; Mirzai B; Augustson BM; Erber WN
    J Clin Pathol; 2022 Jan; 75(1):50-57. PubMed ID: 33234694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A counting strategy for estimating plasma cell number in CD138-stained bone marrow core biopsy sections.
    Smith FB; Elnawawi A
    Ann Clin Lab Sci; 2008; 38(2):138-42. PubMed ID: 18469359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.